Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children

Clinical Infectious Diseases

Volumn 40, Issue 8, 2005, Pages 1181-1187

  Pelton, Stephen I ^a   Stanley, Kenneth ^b   Yogev, Ram ^e,f   Fletcher, Courtney V ^g   McIntosh, Kenneth ^c,d   Wiznia, Andrew ^h   Nachman, Sharon ⁱ  

^a BOSTON MEDICAL CENTER   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; INDINAVIR; LAMIVUDINE; RITONAVIR; STAVUDINE; URIC ACID; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ANURIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG WITHDRAWAL; FEMALE; FLANK PAIN; FOLLOW UP; HEADACHE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY DYSFUNCTION; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; VIRUS LOAD; VOMITING;

ADOLESCENT; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; INFANT; MALE; RITONAVIR; VIRAL LOAD;

EID: 16844380130     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428833     Document Type: Article

References (18)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 20 January 2004. Available at: http://www.aidsinfo.nih. org. Accessed 6 June 2004.
2. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 23 March 2004. Available at: http://www.aidsinfo.nih.org. Accessed 6 June 2004.
3. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA 2000; 283:492-8.
4. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics 2002; 109:1-7.
5. Mueller BU, Sleasman J, Nelson RP, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics 1998; 102:101-9.
6. Crixivan (indinavir sulfate) [package insert]. West Point, PA: Merck, 2002.
7. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother 1998; 42:2784-91.
8. Yogev R, Lee S, Wiznia A, et al. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J 2002; 21:119-25.
9. Gelman R, Cheng SC, Kidd P, Waxdal M, Kagan J. Assessment of the effects of instrumentation, monoclonal antibody, and fluorochrome on flow cytometric immunophenotyping: a report based on 2 years of the NIAID DIADS flow cytometry quality assessment program. Clin Immunol Immunopathol 1993; 66:150-62.
10. Dyer JR, Pilcher CD, Shepard R, Schock J, Eron JJ, Fiscus SA. Comparison of NucliSens and Roche Monitor assays for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1999; 37:447-9.
11. Erali M, Hillyard DR. Evaluation of the ultrasensitive Roche Amplicor HIV-1 Monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J. Clin Microbiol 1999; 37:792-5.
12. Yen-Lieberman B, Brambilla D, Jackson B, et al. Evaluation of a quality assurance program for quantitation of human immunodeficiency virus type 1 RNA in plasma by the AIDS Clinical Trials Group virology laboratories. J Clin Microbiol 1996; 34:2695-701.
13. Brambilla D, Leung S, Lew J, et al. Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard in kit comparisons. J Clin Microbiol 1998; 36:311-4.
14. Hollander M, Wolfe DA. Nonparametric statistical methods. New York: John Wiley, 1973.
15. Burger DM, Hoetelmans RM, Hugen PW, et al. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther 1998; 3:215-20.
16. Fletcher CV, Brundage RC, Remmel RP, et al. Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy. Antimicrob Agents Chemother 2000; 44:1029-34.
17. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for human immunodeficiency virus infection. AIDS 2002; 16:551-60.
18. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV Indinavir concentrations and antiviral effect. Pharmacotherapy 1999; 19:708-12.